On May 30, Jiangxi Yimai Sunshine Group Co., Ltd. (Yimai Sunshine) opened a stock offering, which will end on June 4. It is expected to be listed on the main board of the Hong Kong Stock Exchange on June 7.
The Zhitong Finance App learned that on May 30, Jiangxi Yimai Sunshine Group Co., Ltd. (Yimai Sunshine) opened a stock offering, which will end on June 4, and is expected to be listed on the main board of the Hong Kong Stock Exchange on June 7. Yimai Sunshine plans to issue 17.816 million shares in this IPO. The issuance range is HK$14.60 to HK$16.80 per share, 500 shares per lot, and a maximum capital of about HK$299 million. The sole sponsor of this IPO is CITIC Securities.
According to the prospectus, Yimai Sunshine is a leading medical imaging specialist medical group in China. In 2023, Yimai Sunshine ranked first among all third-party medical imaging center operators in China based on the number of medical imaging center outlets, number of equipment, number of registered radiologists registered as their main workplace, the average number of examinations, and fees paid by patients; in terms of revenue generated by imaging centers in 2023, Yimai Sunshine ranked second among all third party medical imaging centers in China.
Yimai Sunshine's medical imaging center network covers 17 provinces, autonomous regions and municipalities directly under the Central Government, extending from Tier 1 and 2 cities to 59 county-level administrative districts. As of December 31, 2023, the company's medical imaging center network consists of 97 imaging centers, including: 9 flagship imaging centers, 24 regional shared imaging centers, 50 specialist medical consortium imaging centers, and 14 operational management imaging centers.
In addition, Yimei Sunshine's gross margin increased from 29.6% in 2021 to 30.2% in 2022, and further increased to 35.8% in 2023. This was mainly due to the increase in the company's revenue during the record period, and due to the company's brand awareness, competitiveness and chain development, the company achieved economies of scale in the imaging center business.
Notably, since 2016, the company has completed multiple rounds of pre-IPO investments. The company's main pre-IPO investors include Beijing Goldman Sachs, Baishan Investment, CICC Yingrun, Beijing People's Insurance, JD Yingzheng, and OrbiMed.